Overview
The marketing authorisation for LeukoScan has been withdrawn at the request of the marketing authorisation holder.
LeukoScan : EPAR - Summary for the public
English (EN) (516.27 KB - PDF)
български (BG) (716 KB - PDF)
español (ES) (517.76 KB - PDF)
čeština (CS) (685.63 KB - PDF)
dansk (DA) (517.71 KB - PDF)
Deutsch (DE) (519.14 KB - PDF)
eesti keel (ET) (516.76 KB - PDF)
ελληνικά (EL) (711.69 KB - PDF)
français (FR) (516.17 KB - PDF)
italiano (IT) (519.32 KB - PDF)
latviešu valoda (LV) (690.36 KB - PDF)
lietuvių kalba (LT) (656.6 KB - PDF)
magyar (HU) (676.17 KB - PDF)
Malti (MT) (688.96 KB - PDF)
Nederlands (NL) (518.44 KB - PDF)
polski (PL) (691.01 KB - PDF)
português (PT) (520.24 KB - PDF)
română (RO) (650.61 KB - PDF)
slovenčina (SK) (680.33 KB - PDF)
slovenščina (SL) (673.42 KB - PDF)
Suomi (FI) (516.88 KB - PDF)
svenska (SV) (517.53 KB - PDF)
Product information
LeukoScan : EPAR - Product Information
English (EN) (611.18 KB - PDF)
български (BG) (1.27 MB - PDF)
español (ES) (624.63 KB - PDF)
čeština (CS) (1.06 MB - PDF)
dansk (DA) (670.18 KB - PDF)
Deutsch (DE) (623.7 KB - PDF)
eesti keel (ET) (616.86 KB - PDF)
ελληνικά (EL) (1.25 MB - PDF)
français (FR) (684.89 KB - PDF)
hrvatski (HR) (752.92 KB - PDF)
íslenska (IS) (612.91 KB - PDF)
italiano (IT) (613.84 KB - PDF)
latviešu valoda (LV) (1.15 MB - PDF)
lietuvių kalba (LT) (786.25 KB - PDF)
magyar (HU) (1.03 MB - PDF)
Malti (MT) (975.04 KB - PDF)
Nederlands (NL) (622.94 KB - PDF)
norsk (NO) (606.27 KB - PDF)
polski (PL) (1.08 MB - PDF)
português (PT) (679.29 KB - PDF)
română (RO) (733.17 KB - PDF)
slovenčina (SK) (1.04 MB - PDF)
slovenščina (SL) (1.03 MB - PDF)
Suomi (FI) (610.22 KB - PDF)
svenska (SV) (667.87 KB - PDF)
Latest procedure affecting product information: IAIN/0024/G
18/01/2017
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
LeukoScan : EPAR - All Authorised presentations
English (EN) (466.59 KB - PDF)
Product details
- Name of medicine
- LeukoScan
- Active substance
- sulesomab
- International non-proprietary name (INN) or common name
- sulesomab
- Therapeutic area (MeSH)
- Osteomyelitis
- Radionuclide Imaging
- Anatomical therapeutic chemical (ATC) code
- VO4D
Pharmacotherapeutic group
Diagnostic agentsTherapeutic indication
This medicinal product is for diagnostic use only.
LeukoScan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.
LeukoScan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia.
Authorisation details
- EMA product number
- EMEA/H/C/000111
- Marketing authorisation holder
- Immunomedics GmbH
Otto-Röhm-Straße 69
D-64293 Darmstadt
Germany - Marketing authorisation issued
- 14/02/1997
- Revision
- 7
Assessment history
LeukoScan : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (566.84 KB - PDF)
LeukoScan : EPAR - Steps taken after authorisation when a cutoff date has been used
English (EN) (571.74 KB - PDF)
More information on LeukoScan
Public statement on LeukoScan: Withdrawal of the marketing authorisation in the European Union
English (EN) (59 KB - PDF)